NYMX
(COMTEX) B: Nymox's AD7C Test Found to Be Highly Attractive and Usefu
B: Nymox's AD7C Test Found to Be Highly Attractive and Useful in New Journal
Publication
KENSINGTON, Md., Mar 21, 2000 (BUSINESS WIRE) -- A new peer- reviewed
article in the scientific journal Alzheimer's Reports has affirmed the
value of the AD7C(TM) test currently being provided by Nymox
Pharmaceutical Corporation (Nasdaq:NYMX) exclusively through its
CLIA-certified reference laboratory in Kensington, Maryland.
The article, entitled "AD7C-NTP biomarker for Alzheimer's disease" and
published in Alzheimer's Reports (Vol. 2, No. 6, pages 327-332), was
written by Dr. Suzanne de la Monte of Harvard University, Rhode Island
Hospital and Brown University School of Medicine and colleagues. Dr. de
la Monte is one of the principal investigators at Harvard University
who made the initial discovery of the relationship between AD7C-NTP, a
brain protein, and Alzheimer's disease.
According to the article, there is "solid evidence that both the
cerebrospinal fluid and urine assays for AD7C-NTP can be used as
surrogate markers and diagnostic aids to detect possible or probable
Alzheimer's disease. Importantly, the AD7C-NTP assays have demonstrated
value for ruling out the diagnosis of Alzheimer's disease and alerting
caretakers to pursue other potential causes of dementia or cognitive
impairment."
The article also states, "The AD7C test can be used to screen patients
for possible or probable AD and thereby facilitate the selection of
individuals for enrolment in clinical therapeutic trials. Moreover the
AD7C assay can be used to monitor progression of disease since the
levels in CSF increase with severity of AD dementia. By the same token,
the AD7C test can provide an objective and rapid index for gauging
beneficial responses in therapeutic intervention. The high degree of
specificity and sensitivity afforded by the AD7C assay make it highly
attractive and useful as a diagnostic aid for early possible and
probable AD."
The paper provides an extensive review of the discovery of AD7C-NTP and
the gene that produces it and of the biochemical, immunohistological,
in vitro and clinical evidence that links this protein to Alzheimer's
disease.
Dr. Michael Munzar, Medical Director of Nymox, said, "The article is an
excellent contribution to the exciting underlying science of our AD7C
test."
Nymox Pharmaceutical Corporation pioneers in the research and
development of products for the diagnosis and treatment of Alzheimer's
disease, an affliction of more than 20 million people around the world.
Nymox offers the world's only accurate, non-invasive test to aid in the
diagnosis of the disease, and is developing proprietary spheron-based
drug therapies that could lead to effective treatment of Alzheimer's
disease.
Nymox is also developing a new class of antibacterial agents for the
treatment of urinary tract and other bacterial infections in humans
which have proved highly resistant to conventional antibiotic
treatments and for the treatment of E. coli 0157:H7 bacterial
contamination in hamburger meat and other food and drink products.
Nymox recently acquired a majority interest in Serex, Inc., a New
Jersey corporation with proprietary tests under development in the
fields of geriatric, cardiovascular, metabolic and musculoskeletal
disease.
Nymox Pharmaceutical Corporation is headquartered in Montreal, with
facilities in Kensington, Md., and Maywood, N.J. Its stock is traded on
Nasdaq with the symbol NYMX. More information is available at
nymox.com.
This press release contains certain forward-looking statements as
defined in the United States Private Securities Litigation Reform Act
of 1995, that involve a number of risks and uncertainties. There can be
no assurance that such statements will prove to be accurate, and the
actual results and future events could differ materially from
management's current expectations. Such factors are detailed from time
to time in Nymox's filings with the United States Securities and
Exchange Commission and other regulatory authorities.
Copyright (C) 2000 Business Wire. All rights reserved.
Distributed via COMTEX.
-0-
CONTACT: Nymox Pharmaceutical Corporation, Kensington
Dr. Michael Munzar, 800/93NYMOX
or
Sitrick and Company, Los Angeles
Lew Phelps, 310/788-2850, ext. 4103
WEB PAGE: businesswire.com
GEOGRAPHY: MARYLAND MASSACHUSETTS RHODE ISLAND NEW JERSEY
INDUSTRY CODE: PHARMACEUTICAL
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlin |
